Less abdominal pain
SKYRIZI RESULTS
Take Control of Crohn’s With RELIEF, REPAIR, and REMISSION
SKYRIZI can help deliver significant symptom relief, visible repair* of intestinal lining damage, and remission.
*Areas visually assessed may not represent total resolution or repair of the entire intestinal lining or deeper bowel layers. Visible repair is defined as at least a 50% improvement of the intestinal lining.
*Areas visually assessed may not represent total resolution or repair of the entire intestinal lining or deeper bowel layers. Visible repair is defined as at least a 50% improvement of the intestinal lining.
Visible REPAIR* of Intestinal Lining Damage
AT 12 WEEKS
In two induction trials 36%† achieved visible repair* of intestinal lining damage
600 mg IV‡ starter infusion
AT 1 YEAR
Of those who were eligible and entered a maintenance trial§
50%§ achieved visible repair* of intestinal lining damage
180 mg SC|| maintenance injection
And 48%§ with 360 mg SC|| maintenance injection.
Your doctor will decide what maintenance dose is right for you.
*Areas visually assessed may not represent total resolution or repair of the entire intestinal lining or deeper bowel layers. Visible repair is defined as at least a 50% improvement of the intestinal lining.
See REAL IMAGES Below
Click to compare
Real clinical trial endoscopy images from a bio-naïve patient who received SKYRIZI 600 mg during induction and 180 mg during maintenance. Based on endoscopy, patient saw visible improvement of intestinal lining at 12 weeks and 1 year.
In clinical trials, some people on SKYRIZI saw little to no evidence of active Crohn's of the intestinal lining at 12 weeks and at 1 year. In the maintenance trial, this measure was not tested for a difference between SKYRIZI and placebo at 1 year. Results at 1 year measured among those who were eligible and entered a maintenance trial.§ All results are based on areas that were assessed on endoscopy.
Individual results may vary.
REMISSION
SKYRIZI IS THE ONLY IL-23 INHIBITOR PROVEN TO HELP SOME PEOPLE ACHIEVE REMISSION AS EARLY AS 4 WEEKS¶
¶In clinical trials, approximately 18% of people achieved clinical remission at 4 weeks.
AT 12 WEEKS
In two induction trials
44%† of patients achieved remission
600 mg IV‡ starter infusion
AT 1 YEAR
Of those who were eligible and entered a maintenance trial,§
61%§ achieved remission
180 mg SC|| maintenance injection
And 57%§ with 360 mg SC|| maintenance injection.
Your doctor will decide what maintenance dose is right for you.
AT 4 YEARS
In another trial, SKYRIZI helped
people with remission#
#Results at 1 and 4 years measured in SKYRIZI patients who met clinical response (decrease of CDAI score by >/=100 points) at 12 weeks. In the less strict study at 4 years, everyone knew SKYRIZI was used, which may have influenced results.
Individual results may vary.
†Results are combined from 2 clinical trials of 527 patients: one included patients with or without prior biologic failure and the other included patients with prior biologic failure.
‡Intravenous infusion (through a vein in the arm).
§Results from 252 patients who achieved clinical response defined as a reduction in CDAI of at least 100 points from baseline after 12 weeks of treatment with SKYRIZI.
||Subcutaneous injection (under the skin).
JONATHAN,
a SKYRIZI Crohn’s Patient, Shares His Experience
With SKYRIZI,
I ACHIEVED REMISSION
AT 1 YEAR. It was a fantastic feeling.
I ACHIEVED REMISSION
AT 1 YEAR. It was a fantastic feeling.
Discuss with your doctor to see if SKYRIZI is appropriate for you.
Up Next
Talk to your doctor about your symptoms and treatment options.
Recommended for You
Learn how SKYRIZI can be administered at home after 3 starter doses and proper training by a healthcare professional.